Brought to you by 
British Biotech, Serono ally on inflammatory diseases
27 Apr 2021
Executive Summary
Combining British Biotech's expertise in metalloenzyme inhibition (MEI) and Serono's in multiple sclerosis and other inflammatory diseases, the companies will identify, develop, and market a treatment for inflammation. The deal could be worth $30-80mm.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
British Biotech, Serono ally on inflammatory diseases
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice